May 17, 2017 - By Adrian Mccoy
The stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) is a huge mover today! About 149,244 shares traded. Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) has risen 6.00% since April 17, 2017 and is uptrending. It has by 0.00% the S&P500.The move comes after 5 months positive chart setup for the $65.98 million company. It was reported on May, 17 by Barchart.com. We have $2.35 PT which if reached, will make NASDAQ:NVIV worth $1.98 million more.
Terra Nitrogen Company, L.P. is a limited partnership that produces nitrogen fertilizer products. The company has market cap of $1.50 billion. The Company’s principal products are anhydrous ammonia (ammonia) and urea ammonium nitrate solutions (UAN), which it makes at its facility in Verdigris, Oklahoma. It has a 10.09 P/E ratio. The Company’s nitrogen products are used primarily by farmers.
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The company has market cap of $65.98 million. The Firm is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries . It currently has negative earnings. The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Bridgecreek Investment Management Llc holds 1.51% of its portfolio in Terra Nitrogen Company, L.P. for 51,975 shares. Bowen Hanes & Co Inc owns 102,000 shares or 0.56% of their US portfolio. Moreover, S&T Bank Pa has 0.41% invested in the company for 24,766 shares. The Vermont-based Maple Capital Management Inc. has invested 0.26% in the stock. Rafferty Asset Management Llc, a New York-based fund reported 24,799 shares.
Analysts await Terra Nitrogen Company, L.P. (NYSE:TNH) to report earnings on August, 2.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.